Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery.
about
The Future of Smallpox Vaccination: is MVA the key?Susceptibility of different leukocyte cell types to Vaccinia virus infectionPoxvirus vectors as HIV/AIDS vaccines in humansRecombinant vaccines against T. gondii: comparison between homologous and heterologous vaccination protocols using two viral vectors expressing SAG1Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpoxRabies Control and Treatment: From Prophylaxis to Strategies with Curative PotentialPoxvirus tropismCandidate influenza vaccines based on recombinant modified vaccinia virus Ankara.Strategies towards universal pandemic influenza vaccines.MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization.Human immunodeficiency virus vaccine trialsExperimental vaccines against potentially pandemic and highly pathogenic avian influenza virusesModified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccinesSafety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responsesIntroduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice.Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigensCellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene.Interplay between modified vaccinia virus Ankara and dendritic cells: phenotypic and functional maturation of bystander dendritic cells.A mechanism for the inhibition of DNA-PK-mediated DNA sensing by a virus.Expression of CCL20 and granulocyte-macrophage colony-stimulating factor, but not Flt3-L, from modified vaccinia virus ankara enhances antiviral cellular and humoral immune responses.Next generation: tuberculosis vaccines that elicit protective CD8+ T cellsModified vaccinia virus Ankara triggers type I IFN production in murine conventional dendritic cells via a cGAS/STING-mediated cytosolic DNA-sensing pathwayRecombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge.Viral vector-based therapeutic cancer vaccinesDeletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve ImmunogenicityVaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1.The vaccinia virus O1 protein is required for sustained activation of extracellular signal-regulated kinase 1/2 and promotes viral virulence.The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.Production of prostaglandin E₂ in response to infection with modified vaccinia Ankara virusDevelopments towards effective treatments for Nipah and Hendra virus infection.Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines.Deletion of A44L, A46R and C12L Vaccinia Virus Genes from the MVA Genome Improved the Vector Immunogenicity by Modifying the Innate Immune Response Generating Enhanced and Optimized Specific T-Cell Responses.Vaccinia virus protein K7 is a virulence factor that alters the acute immune response to infectionThe heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays.Targeted strategies for henipavirus therapeuticsThe attenuated NYCBH vaccinia virus deleted for the immune evasion gene, E3L, completely protects mice against heterologous challenge with ectromelia virus.Viral vector vaccines expressing nucleoprotein and phosphoprotein genes of avian bornaviruses ameliorate homologous challenge infections in cockatiels and common canariesPrime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.
P2860
Q24801195-A5B4D982-9C75-4591-BF97-2D7E9C900222Q24801903-0A249BC5-A860-4356-AAD5-6E7700745052Q26995078-2D1ED9E9-BFBC-426D-AF03-6CA6EE3D683FQ27321063-4DA88DF7-691D-4C38-8B95-DC3BD59F8E91Q27346933-CD767F81-C32A-4B67-912C-BBA049C92980Q28076429-D352E540-83F4-4216-8E39-17C7157A4187Q28237434-DCB27AC3-DEF6-469D-AA0E-2B7F586B6C8DQ30375979-FD621555-52F9-421A-BC47-16590AD5C8F5Q30382226-2DAF46DE-C6B8-47C5-8772-AC27663F3742Q30382567-0B009C71-4606-49B5-BB96-710CAF81B733Q30424366-B95F7D8B-DA82-4FF2-945C-6F03EAA4AE01Q30427591-5B353C4C-70BB-4D5F-A276-54C5736ED5C7Q33653229-6AD0EC91-BA9D-4F43-B6A5-D61F75E0FFB2Q33875160-D1A0FE3A-D176-433E-B96F-177A5397A706Q34055541-5917D191-0344-4292-8214-5FCE817A2E32Q34120696-B90EE57A-9D54-4779-9375-1813FC907C38Q34465228-86BA715E-A6FF-4410-A267-64FAADA028B6Q34651266-036E32AA-B03D-4B74-89D4-9F8235187670Q34982651-44F28F54-CBCE-4C2D-9FDF-3B426286796FQ35008790-34422E8D-3A2A-48A9-BE04-E69236CE61EEQ35023778-01468934-2000-4D0F-8660-902BD585C6A4Q35099708-18ECC2EB-607B-4DFB-A7C4-163DBEDD3903Q35151746-3B4EA64A-28A4-45DB-A4D6-6D4A5FE5FE25Q35238179-6BCF2709-EE61-4F75-8CD5-AF5DB2A3F115Q35515080-93BF8B11-2BC0-4567-B585-5B075E6C70ECQ35656345-C97A58B1-926A-48A5-92A2-8A10358D8E69Q35751946-73EF8FF2-10DE-483A-988D-D180D2CF1D6FQ35826480-522EC04F-29F3-4671-A0C4-1EAFEE5F8FBAQ35867988-BCBCCAEF-3FF5-47D1-9B41-99DC26A0D396Q35962511-91003A21-AB65-4ABA-9E5E-642FB3F8CC8CQ36379335-16B95F78-85FB-4257-A163-115C30B15C6EQ36727280-07C7814F-9696-4F55-937E-DCCFF27E6A1FQ36849770-F63EEEF3-FD9A-44D1-B05F-52B446A2FCADQ36947039-198A766C-9AA5-4E63-80EE-E36E027CA0CCQ37006800-3A0E8972-34B0-4C07-9C2C-5BF7E53F3410Q37169163-4D27DB08-4DBD-4343-9D68-4D909CC404D4Q37175177-FAA64CEC-D322-4FED-BED0-3E4DB1EFE83CQ37211150-1D7AB7B1-85DD-435E-944B-2576EC882313Q37405702-078D3361-CE5C-4A8F-84C2-2C11EE7B721CQ37785949-65223386-41A5-478A-951B-24EF03A113A4
P2860
Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Vaccinia vectors as candidate ...... s Ankara for antigen delivery.
@ast
Vaccinia vectors as candidate ...... s Ankara for antigen delivery.
@en
type
label
Vaccinia vectors as candidate ...... s Ankara for antigen delivery.
@ast
Vaccinia vectors as candidate ...... s Ankara for antigen delivery.
@en
prefLabel
Vaccinia vectors as candidate ...... s Ankara for antigen delivery.
@ast
Vaccinia vectors as candidate ...... s Ankara for antigen delivery.
@en
P356
P1476
Vaccinia vectors as candidate ...... s Ankara for antigen delivery.
@en
P2093
Caroline Staib
P304
P356
10.2174/1568005033481123
P50
P577
2003-09-01T00:00:00Z